论文部分内容阅读
肺炎链球菌是引起全球所有年龄组高发病率和病死率的主要病原菌。目前投入使用的有23价荚膜多糖疫苗和7价多糖蛋白结合疫苗。荚膜多糖疫苗有许多局限性,蛋白结合疫苗是对其改进,但也不能完全取代它。两者都具有一定效力和良好的安全性,其中蛋白结合疫苗具有更好的免疫原性。此外,其他多价结合疫苗也已进入临床试验阶段。蛋白疫苗、DNA疫苗、联合疫苗、活疫苗也在研制和开发中。
Streptococcus pneumoniae is the leading cause of high morbidity and mortality in all age groups worldwide. Currently put into use 23 capsular polysaccharide vaccine and 7 polyvalent protein conjugate vaccine. There are many limitations of capsular polysaccharide vaccine, protein-binding vaccine is to improve it, but it can not completely replace it. Both have some efficacy and good safety, of which the protein-binding vaccine has better immunogenicity. In addition, other multivalent conjugate vaccines have also entered the clinical trial phase. Protein vaccines, DNA vaccines, combination vaccines and live vaccines are also under development and development.